![](https://endpts.com/wp-content/uploads/2023/06/Matt-Kapusta-uniQure-tile.jpg)
Matt Kapusta, uniQure CEO
UniQure unveils mixed Huntington's gene therapy data, shares tank
UniQure shared updated data from a Phase I/II study that showed a clinical benefit in a small group of patients with Huntington’s disease who received …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.